1,045 reports of this reaction
1.4% of all APREPITANT reports
#11 most reported adverse reaction
FEBRILE NEUTROPENIA is the #11 most commonly reported adverse reaction for APREPITANT, manufactured by Merck Sharp & Dohme LLC. There are 1,045 FDA adverse event reports linking APREPITANT to FEBRILE NEUTROPENIA. This represents approximately 1.4% of all 73,587 adverse event reports for this drug.
Patients taking APREPITANT who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for APREPITANT, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for APREPITANT:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 1,045 FDA reports for APREPITANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 1.4% of all adverse event reports for APREPITANT, making it a notable side effect.
If you experience febrile neutropenia while taking APREPITANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.